Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294763" target="_blank" >RIV/00216208:11110/15:10294763 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10294763

Výsledek na webu

<a href="http://dx.doi.org/10.1111/bjh.13138" target="_blank" >http://dx.doi.org/10.1111/bjh.13138</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/bjh.13138" target="_blank" >10.1111/bjh.13138</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

Popis výsledku v původním jazyce

The primary objective of this study was to investigate factors associated with fatigue severity in newly diagnosed patients with higher-risk myelodysplastic syndromes (MDS). The secondary objectives were to assess symptom prevalence and to examine the relationships between fatigue, quality of life (QoL) and overall symptom burden in these patients. The analyses were conducted in 280 higher-risk MDS patients. Pre-treatment patient-reported fatigue was evaluated with the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale and QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Female gender (P=0018), poor performance status (i.e., ECOG of 2-4) (P<0001) and lower levels of haemoglobin (Hb) (P=0026) were independently associated with higher fatigue severity. The three most prevalent symptoms were as follows: fatigue (92%), dyspnoea (63%) and pain (55%). Patients with higher levels of

Název v anglickém jazyce

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

Popis výsledku anglicky

The primary objective of this study was to investigate factors associated with fatigue severity in newly diagnosed patients with higher-risk myelodysplastic syndromes (MDS). The secondary objectives were to assess symptom prevalence and to examine the relationships between fatigue, quality of life (QoL) and overall symptom burden in these patients. The analyses were conducted in 280 higher-risk MDS patients. Pre-treatment patient-reported fatigue was evaluated with the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale and QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Female gender (P=0018), poor performance status (i.e., ECOG of 2-4) (P<0001) and lower levels of haemoglobin (Hb) (P=0026) were independently associated with higher fatigue severity. The three most prevalent symptoms were as follows: fatigue (92%), dyspnoea (63%) and pain (55%). Patients with higher levels of

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

British Journal of Haematology

ISSN

0007-1048

e-ISSN

—

Svazek periodika

168

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

361-370

Kód UT WoS článku

000348845500007

EID výsledku v databázi Scopus

2-s2.0-84921434407